Immunome (NasdaqCM:IMNM) FY Conference Transcript

Immunome (NasdaqCM:IMNM) FY Conference Summary Company Overview - Company: Immunome - Event: 44th J.P. Morgan Healthcare Conference - Date: January 14, 2026 Core Industry Focus - Industry: Biotechnology, specifically in targeted oncology therapies Key Points and Arguments AL102 Development - Drug Description: AL102 is an oral gamma-secretase inhibitor for treating desmoid tumors, administered once daily [4][5] - Clinical Progress: Positive top-line data reported in December, with plans to submit a New Drug Application (NDA) in Q2 2026 [5][8] - Efficacy Data: - Hazard ratio of 0.16, indicating strong efficacy [8] - Objective response rate of 56% based on strict FDA criteria [8][16] - Median tumor reduction of 83% [8][16] - Patient Population: Approximately 10,000-11,000 patients in the U.S. actively managed for desmoid tumors annually [10][17] Competitive Landscape - Comparison with Nirogacestat: AL102 is positioned as a better option due to superior pharmacokinetics and a more user-friendly dosing schedule [11][12][47] - Historical Context: Previous treatments had lower response rates (20% pre-2018, 33% with Sorafenib in 2018, and 41% with Nirogacestat in 2023) [16] ADC Program - ROR1 ADC (IM-1021): - Focus on liquid tumors, particularly B-cell lymphomas [22][26] - Development of a diagnostic tool for ROR1 to enhance treatment targeting [22] - Objective responses observed in early trials, with plans for further expansion [23][26] - HC74 Platform: A new ADC technology that improves therapeutic index and overcomes resistance mechanisms [27][30] Radioligand Development - FAP Targeting: A radioligand targeting fibroblast activation protein (FAP), which binds to 75% of solid tumors [35][36] - Clinical Trials: FDA clearance obtained, with trials expected to start soon [36][39] Financial Position - Cash Position: Sufficient funding to extend operations into 2028 [6] Future Outlook - Upcoming Submissions: Plans to submit three INDs for solid tumor ADCs and the FAP radioligand within the year [39][64] - Investor Expectations: Anticipation of FDA approval for AL102 and significant clinical data releases by the end of 2026 [63][64] Additional Important Information - Safety Profile: AL102 has a generally well-tolerated safety profile, with common adverse events being manageable [15] - Market Strategy: Focus on making AL102 accessible to the 10-11,000 patients actively managed for desmoid tumors, leveraging a modest sales force [18] This summary encapsulates the critical insights from the Immunome conference, highlighting the company's innovative approaches in oncology and its strategic positioning in the biotechnology sector.